Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that it has selected Destum Partners to assist in finding a development partner for its psoriasis compound, KM-133. Cellceutix management has carefully evaluated which direction to take in the development of KM-133 and has concluded that this is the best way to create shareholder value. In a human xenograft animal model of psoriasis, KM-133 reduced psoriasis significantly more than controls...
More...
More...